CY1110782T1 - Αλατα προσθηκης αναστολεων του ενζυμου μετατροπης της αγγειοτασινης με οξεα δοτες no, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν - Google Patents

Αλατα προσθηκης αναστολεων του ενζυμου μετατροπης της αγγειοτασινης με οξεα δοτες no, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν

Info

Publication number
CY1110782T1
CY1110782T1 CY20101100834T CY101100834T CY1110782T1 CY 1110782 T1 CY1110782 T1 CY 1110782T1 CY 20101100834 T CY20101100834 T CY 20101100834T CY 101100834 T CY101100834 T CY 101100834T CY 1110782 T1 CY1110782 T1 CY 1110782T1
Authority
CY
Cyprus
Prior art keywords
converting enzyme
convertants
salts
preparation
addition
Prior art date
Application number
CY20101100834T
Other languages
English (en)
Inventor
Nanteuil Guillaume De
Bernard Portevin
Philippe Gloanec
Jean Gilles Parmentier
Alain Benoist
Tony Verbeuren
Alain Rupin
Christine Courchay
Serge Simonet
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39539691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110782(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1110782T1 publication Critical patent/CY1110782T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Ενώσεις του τύπου (I): (A)m · (B)n (I) στον οποίο το Α παριστάνει μια ένωση αναστολέα του ενζύμου μετατροπής της αγγειοτασίνης η οποία περιέχει μια τουλάχιστον βασική ομάδα που μπορεί να σχηματίζει άλας, το Β παριστάνει μια ένωση η οποία περιέχει μια τουλάχιστον όξινη ομάδα που μπορεί να σχηματίζει άλας και τουλάχιστον μια ομάδα δότη NO, το m παριστάνει τον αριθμό των όξινων ομάδων που έχουν σχηματίσει άλας και το n παριστάνει τον αριθμό των βασικών ομάδων του Α που έχουν σχηματίσει άλας, όπου εννοείται ότι ο ή οι δεσμοί μεταξύ Α και Β είναι ιοντικού τύπου. Φάρμακα.
CY20101100834T 2007-09-21 2010-09-15 Αλατα προσθηκης αναστολεων του ενζυμου μετατροπης της αγγειοτασινης με οξεα δοτες no, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν CY1110782T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0706629A FR2921365B1 (fr) 2007-09-21 2007-09-21 Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP08290885A EP2039682B1 (fr) 2007-09-21 2008-09-19 Sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine avec des acides donneurs de NO, leur procédé de préparation et les compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
CY1110782T1 true CY1110782T1 (el) 2015-06-10

Family

ID=39539691

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100834T CY1110782T1 (el) 2007-09-21 2010-09-15 Αλατα προσθηκης αναστολεων του ενζυμου μετατροπης της αγγειοτασινης με οξεα δοτες no, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν

Country Status (43)

Country Link
US (1) US7981920B2 (el)
EP (2) EP2039682B1 (el)
JP (1) JP4903187B2 (el)
KR (1) KR101070056B1 (el)
CN (1) CN101391973A (el)
AP (1) AP2010005204A0 (el)
AR (1) AR068488A1 (el)
AT (1) ATE476416T1 (el)
AU (1) AU2008217013B8 (el)
BR (1) BRPI0804073A2 (el)
CA (1) CA2639700C (el)
CL (1) CL2008002725A1 (el)
CR (1) CR11320A (el)
CY (1) CY1110782T1 (el)
DE (1) DE602008002027D1 (el)
DK (1) DK2039682T3 (el)
EA (1) EA015092B1 (el)
EC (1) ECSP10010040A (el)
ES (1) ES2349493T3 (el)
FR (1) FR2921365B1 (el)
GE (1) GEP20125479B (el)
HN (1) HN2010000533A (el)
HR (1) HRP20100545T1 (el)
JO (1) JO2664B1 (el)
MA (1) MA30320B1 (el)
MX (1) MX2008011954A (el)
MY (1) MY144927A (el)
NI (1) NI201000038A (el)
NZ (1) NZ572988A (el)
PA (1) PA8796701A1 (el)
PE (1) PE20091190A1 (el)
PL (1) PL2039682T3 (el)
PT (1) PT2039682E (el)
RS (1) RS51433B (el)
SA (1) SA08290599B1 (el)
SG (1) SG151200A1 (el)
SI (1) SI2039682T1 (el)
SV (1) SV2010003511A (el)
TN (1) TN2010000111A1 (el)
TW (1) TWI370118B (el)
UY (1) UY31339A1 (el)
WO (1) WO2009074733A2 (el)
ZA (1) ZA200808062B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
WO2013185124A1 (en) * 2012-06-08 2013-12-12 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
CN103848795B (zh) * 2014-03-07 2016-08-17 山东大学 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4218582A1 (de) * 1992-06-05 1993-12-09 Cassella Ag Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
EP1235563A2 (en) * 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
DE10033580A1 (de) 2000-04-10 2001-10-11 Bayer Ag Verfahren zur Herstellung von Ditaurin und seinen Salzen
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
WO2004050084A2 (en) * 2002-11-29 2004-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2006078995A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
AU2006227439A1 (en) * 2005-03-18 2006-09-28 Nicox S.A. Organic nitric oxide enhancing salts of angiotensin converting enzyme inhibitors, compositions and methods of use
RU2271202C1 (ru) * 2005-05-04 2006-03-10 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
CA2630805A1 (en) * 2005-11-23 2007-05-31 Nicox S.A. Salicylic acid derivatives

Also Published As

Publication number Publication date
CL2008002725A1 (es) 2009-06-12
PT2039682E (pt) 2010-09-27
EP2039682A1 (fr) 2009-03-25
CA2639700C (fr) 2012-08-28
SV2010003511A (es) 2010-07-29
DK2039682T3 (da) 2010-11-08
HRP20100545T1 (hr) 2010-11-30
TN2010000111A1 (fr) 2011-09-26
MY144927A (en) 2011-11-30
PE20091190A1 (es) 2009-08-09
NZ572988A (en) 2010-07-30
KR20090031298A (ko) 2009-03-25
AU2008217013A1 (en) 2009-04-09
EA015092B1 (ru) 2011-06-30
AR068488A1 (es) 2009-11-18
WO2009074733A2 (fr) 2009-06-18
MA30320B1 (fr) 2009-04-01
RS51433B (en) 2011-04-30
AU2008217013A8 (en) 2012-10-04
UY31339A1 (es) 2008-10-31
PL2039682T3 (pl) 2010-10-29
MX2008011954A (es) 2009-03-20
SG151200A1 (en) 2009-04-30
TW200920352A (en) 2009-05-16
FR2921365A1 (fr) 2009-03-27
JP2009137935A (ja) 2009-06-25
DE602008002027D1 (de) 2010-09-16
ES2349493T3 (es) 2011-01-04
CA2639700A1 (fr) 2009-03-21
JP4903187B2 (ja) 2012-03-28
SI2039682T1 (sl) 2010-10-29
PA8796701A1 (es) 2009-09-17
ECSP10010040A (es) 2010-04-30
NI201000038A (es) 2010-07-15
KR101070056B1 (ko) 2011-10-04
US20090082393A1 (en) 2009-03-26
SA08290599B1 (ar) 2011-05-04
EP2039682B1 (fr) 2010-08-04
GEP20125479B (en) 2012-04-25
EP2236495A1 (fr) 2010-10-06
US7981920B2 (en) 2011-07-19
TWI370118B (en) 2012-08-11
CN101391973A (zh) 2009-03-25
AP2010005204A0 (en) 2010-04-30
CR11320A (es) 2010-06-29
JO2664B1 (en) 2012-06-17
BRPI0804073A2 (pt) 2009-06-16
FR2921365B1 (fr) 2012-10-12
WO2009074733A3 (fr) 2009-08-20
ZA200808062B (en) 2009-11-25
EA200801863A1 (ru) 2009-04-28
HN2010000533A (es) 2013-07-08
ATE476416T1 (de) 2010-08-15
AU2008217013B8 (en) 2012-10-04
AU2008217013B2 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
CY1106577T1 (el) Δερματικο συστημα χορηγησης για παραγωγα αμινολεβουλινικου οξεος
CY1119784T1 (el) Ακετυλιωμενες σαλικυλικες ενωσεις λιπαρου οξεος και οι χρησεις αυτων
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
CY1110489T1 (el) Παραγωγα ισοκινολινης
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CY1113757T1 (el) Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων
EA201170772A1 (ru) Органические соединения
ECSP10010246A (es) Inhibidores de beta-lactamasa
CR20120104A (es) Compuestos quimicos
BR112014013974A2 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
CY1113177T1 (el) Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων
CY1112490T1 (el) Σταθεροποιητες για εμβολια ξηρανθεντα δια καταψυξεως
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
CY1113911T1 (el) Παραγωγα sf5 ως αναστολεις par1, η παρασκευη τους και η χρηση τους ως φαρμακα
EA200800393A1 (ru) Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат
CY1116266T1 (el) Σταθερα αλατα της s-αδενοσυλμεθειονινης και μεθοδος παρασκευης τους
CY1110782T1 (el) Αλατα προσθηκης αναστολεων του ενζυμου μετατροπης της αγγειοτασινης με οξεα δοτες no, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν
CY1104980T1 (el) Μεθοδος για την συλλογη ριζων με ουροκανικο οξυ, παραγωγα και αναλογα
CY1114704T1 (el) Κρυσταλλικη μορφη δ του αλατος αργινινης της περινδοπριλης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις οι οποιες την περιεχουν
CY1112538T1 (el) Μεθοδος για παρασκευη βενζοθειαζεπινων απο γαμμα-αμινοαλκυλβενζολια
AR077429A1 (es) Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
DE602006014001D1 (de) Herstellung von 2-aminothiazol-5-carbonsäurederivaten
CY1116205T1 (el) Μετα χολινης και τρομεθαμινης αλας της λικοφελονης
BR112015024113A2 (pt) derivados de uréia e seu uso como inibidores da proteína de ligação de ácido graxo (fabp)